Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody’s vaccines specifically target Antigen Presenting Cells. By intelligent design, Vaccibody’s vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. The Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases.
Vaccibody’s lead product candidates are VB10.NEO, an individualized therapeutic cancer neoantigen vaccine currently being evaluated in a Phase I/IIa clinical trial and exclusively licensed to Genentech, and VB10.16, a therapeutic cancer vaccine against HPV16-related cancers that is currently being tested in a Phase II clinical trial. Further, Vaccibody has a second generation COVID-19 vaccine program, VB10.COV2. In addition, Vaccibody has collaborations with Roche and Nektar Therapeutics.